A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

This research study is focused on a new medicine called GDC-7035. It's being tested for people who have advanced solid tumours, which means their cancer may have grown or spread. A key part of this study is that it's specifically for those whose cancer has a particular change in its genes, known as a KRAS G12D mutation. This genetic change is important because it can affect how cancer cells grow and behave, and researchers are hoping that GDC-7035 might work by targeting this specific change.

The main aim of this study is to carefully look at how safe GDC-7035 is when given to people. Because it's a new drug, it's very important to understand any side effects it might cause. The study will also explore how the body handles the drug – how much of it gets absorbed, how long it stays in the body, and how it's eventually removed. This information is called pharmacokinetics and helps doctors understand the best way to give the drug.

Finally, the study will also check to see if GDC-7035 shows any early signs of helping to treat the cancer. This means looking to see if tumours shrink or if the cancer stops growing. The researchers will be trying the drug on its own first, and then in combination with other cancer treatments, to see if it works better when used with other medicines. This is an early-stage study, meaning it's one of the first times this drug is being tested in people.